海利品牌怎么样 申请店铺

我要投票 海利在兽药行业中的票数:120 更新时间:2025-02-24
海利是哪个国家的品牌?「海利」是 上海海利生物技术股份有限公司 旗下著名品牌。该品牌发源于上海,由创始人张海明在1981期间创立,经过多年的不懈努力和高速发展,现已成为行业的标杆品牌。

外推网助力海利品牌出海!通过在本页面挂载海利品牌的产品链接和联系邮箱,可以提高海利产品曝光!跨境电商爆单神器,目前只要100元/年哦~

海利怎么样

上海海利生物技术股份有限公司(以下简称“海利生物”)位于上海奉贤经济开发区金海路6720号,其前身为上海松江生物药品厂,是农业部在上海批准生产兽用生物制品的定点企业及农业部在上海设立的动物重大疫情防治生产基地。作为一家专业的动物保健品公司,海利生物能够为预防动物疾病、改善动物福利和提高养殖业主的生产效益提供综合解决方案。海利生物的产品和服务涵盖了家畜、家禽以及宠物等多个领域。

海利生物是上海市高新技术企业、上海市农业产业化重点龙头企业、上海兽用生物制品工程技术研究中心、上海市科技小巨人(培育)企业;海利生物商标被认定为上海市著名商标,公司的疫苗产品荣获“上海名牌”称号;海利生物为上海农林职业技术学院(生物技术专业)的实习培训基地。

海利生物拥有11条GMP生产线,自主生产家畜、家禽两大系列共40多个产品。多年来,海利生物坚持科技创新之路,以市场为导向、以产品为依托,销售网络遍布全国,销售业绩成倍增长。海利生物现有员工近450名,其中专业技术人员占50%以上。海利生物坚持以人为本的人才战略,已建立起经营高效的管理团队、技术精湛的研发团队以及技能娴熟的员工团队。

在企业快速发展中,海利生物高度重视产、学、研相结合的产品战略,以市场为导向,几年来先后与国内行业领先的中国科学院、中国农科院哈尔滨兽医研究所、南京农业大学、河南农业大学等科研机构合作,共同开发具有国内外先进水平的兽用生物疫苗。特别是拥有了猪繁殖与呼吸综合征活疫苗(即蓝耳病活疫苗)、猪圆环病毒2型灭活疫苗(LG株)、猪传染性胃肠炎和流行性腹泻二联灭活疫苗、猪链球菌二联灭活疫苗、鸡新城疫/传染性支气管炎/减蛋综合征/禽流感(H9N2)四联灭活疫苗等国家一、二类新药的知识产权,其中多个新产品的研发及产业化项目获得了上海市科委、上海市经委的科技创新项目立项支持。海利生物的猪繁殖与呼吸综合征活疫苗(即蓝耳病活疫苗)、猪传染性胃肠炎和流行性腹泻二联灭活疫苗、猪圆环病毒2型灭活疫苗、猪链球菌灭活疫苗、高致病性猪繁殖与呼吸综合征活疫苗已先后被认定为上海市科委高新技术成果转化项目,猪链球菌二联灭活疫苗荣获上海市科技进步二等奖。尤其从2007年开始,在全国范围内爆发的猪蓝耳病疫情防治工作中,海利生物承担了农业部定点生产高致病性猪蓝耳病疫苗的重要任务,为广大养殖户提供优质、可靠的疫苗,及时有效地防控了疫情的蔓延。

海利生物致力于为预防畜禽疾病、改善畜禽健康和提高养殖业主的生产效益服务,并能够提供综合解决方案和权威的兽医专家服务系统。为满足市场需求,海利生物一如既往地坚持自主创新及高新技术产业化发展的战略重点,力争跻身国内兽用生物疫苗行业前列。



Shanghai Haili Biotechnology Co., Ltd. (hereinafter referred to as "Haili biology") is located at No. 6720, Jinhai Road, Fengxian Economic Development Zone, Shanghai. Its predecessor is Shanghai Songjiang biological medicine factory. It is a designated enterprise approved by the Ministry of agriculture to produce biological products for animal use in Shanghai and a production base for animal major epidemic prevention and control established by the Ministry of agriculture in Shanghai. As a professional animal health products company, Haili bio can provide comprehensive solutions for preventing animal diseases, improving animal welfare and improving the production efficiency of breeding owners. Haili's products and services cover livestock, poultry and pets. Haili biology is a high-tech enterprise in Shanghai, a key leading enterprise of agricultural industrialization in Shanghai, a research center of animal biological products engineering technology in Shanghai, and a small giant (cultivation) enterprise of science and technology in Shanghai. Haili biology trademark is recognized as a famous trademark in Shanghai, The company's vaccine products won the title of "Shanghai famous brand"; Haili biology is the practice training base of Shanghai Agricultural and Forestry Vocational Technical College (Biotechnology Major). Haili biological has 11 GMP production lines, and independently produces more than 40 products in two series of livestock and poultry. Over the years, Haili biology adheres to the road of scientific and technological innovation, is market-oriented and product-based, with its sales network all over the country, and its sales performance has multiplied. Haili biology has nearly 450 employees, of which more than 50% are professional technicians. Haili biology adheres to the human-oriented talent strategy and has established an efficient management team, a skilled R & D team and a skilled staff team. In the rapid development of the enterprise, Haili biology attaches great importance to the product strategy of combining production, learning and research, and is market-oriented. In recent years, Haili biology has cooperated with Chinese Academy of Sciences, Harbin Veterinary Research Institute of Chinese Academy of Agricultural Sciences, Nanjing Agricultural University, Henan Agricultural University and other scientific research institutions to jointly develop animal biological vaccines with advanced level at home and abroad. In particular, it has the knowledge production of the first and second class new drugs in China, such as the live vaccine of porcine reproductive and respiratory syndrome (i.e. the live vaccine of blue ear disease), the inactivated vaccine of porcine circovirus type 2 (LG strain), the inactivated vaccine of swine infectious gastroenteritis and epidemic diarrhea, the inactivated vaccine of Streptococcus suis, the inactivated vaccine of Newcastle disease / infectious bronchitis / egg drop syndrome / avian influenza (H9N2), etc Among them, R & D and industrialization projects of many new products have been supported by science and technology innovation projects of Shanghai Municipal Commission of science and technology and Shanghai Economic Commission. Haili bio's live vaccine for porcine reproductive and respiratory syndrome (i.e. live vaccine for blue ear disease), bivalent inactivated vaccine for transmissible gastroenteritis and epidemic diarrhea, bivalent inactivated vaccine for porcine circovirus type 2, Streptococcus suis, and highly pathogenic live vaccine for porcine reproductive and respiratory syndrome have been successively recognized as the high-tech achievement transformation project of Shanghai Science and Technology Commission, bivalent inactivated vaccine for Streptococcus suis Won the second prize of Shanghai Science and technology progress award. Especially since 2007, in the prevention and control of the outbreak of blue ear disease nationwide, Haili biology has undertaken the important task of producing highly pathogenic blue ear disease vaccine designated by the Ministry of agriculture, providing high-quality and reliable vaccine for the majority of farmers, and preventing and controlling the spread of the disease in time and effectively. Haili biology is committed to the prevention of livestock and poultry diseases, improve the health of livestock and poultry and improve the production efficiency of breeding owners, and can provide comprehensive solutions and authoritative veterinary expert service system. In order to meet the market demand, Haili biology, as always, adheres to the strategic focus of independent innovation and the development of high-tech industrialization, and strives to be in the forefront of domestic veterinary biological vaccine industry.

本文链接: https://brand.waitui.com/5c9756dfe.html 联系电话:请联系客服添加

千城特选小程序码

7×24h 快讯

2025年民航春运收官,旅客运输量和航班数量均创历史新高

2月23日,中国民航局发布2025年春运期间(1月14日至2月22日)相关运输数据,全国民航累计运输旅客9020万人次,日均225.5万人次,较2024年春运同期增长7.4%,累计保障航班73.9万班,日均1.85万班,比2024年春运同期增长8.3%,旅客运输量和航班数量均创历史新高。全国航班正常率94%,比2024年春运同期增加7个百分点。(证券日报)

2小时前

医药主题基金净值回升,机构瞄准AI医疗投资机会

近期,随着AI医疗概念持续升温,沉寂了较长一段时间的医药板块显现回暖迹象。截至2月20日,多只医药主题基金今年以来净值涨幅超过10%。多家机构认为,经过连续4年的调整,当前医药板块的估值和基金配置比例均处于较低位置,在AI医疗概念带动下,医药板块估值有望迎来重构。(上证报)

2小时前

百度集团:已任命刘晓丹接替Brent Callinicos担任新独立董事及董事会审计委员会主席

36氪获悉,百度集团公告,公司董事会已任命刘晓丹接替Brent Callinicos担任新独立董事及董事会审计委员会主席,于2025年2月23日生效。Callinicos已因个人原因辞任独立董事及董事会审计委员会主席职位。Callinicos的辞任并非因与公司产生任何纠纷或分歧。

2小时前

深化国际业务布局,“A+H”上市热度不减

近日,三一重工、晶澳科技等行业龙头相继公告筹划H股上市,为A股公司赴港上市潮再添几分热度。自去年开始,“A+H”就已成为行业热点。2025年不足两月,就已有近10家A股上市公司官宣赴港上市计划,同时有不少公司公告进展。这批A股公司赴港上市背后,深化国际业务布局是重点战略。业内人士表示,在政策鼓励与企业自身发展需求的双重作用下,包括香港在内的多个境外市场正成为热门选择。(中证网)

2小时前

科技主线热度持续高企,板块内部轮动或加速

上周,A股市场整体走强,科技板块呈现爆发式上涨,AI产业链从上游算力到下游应用均掀起涨停潮,交易资金进一步向科技股集中。机构认为,当前科技板块的成交拥挤度已上升至历史高位,后续板块内部的交易逻辑将逐渐转向基本面。从大势来看,在稳增长政策持续发力,资金风险偏好回暖的背景下,A股有望延续上升趋势。(上证报)

2小时前

本页详细列出关于维尔康的品牌信息,含品牌所属公司介绍,维尔康所处行业的品牌地位及优势。
咨询